I’ve selected a few MABs, which are possible candidates for the treatment of rheumatoid arthritis with a few additions, which could be more useful in psoriatic arthritis. Even if research has been stopped for some, it might not be that the case is closed permanently. Pharmaceutical firm look at the MABs from an investors point of view, that means research will be directed at the most promising MAB first.
Afasevikumab is a human monoclonal IgG1κ antibody targeting IL-17A and IL-17F. There had been a phase 1 trial in “autoimmune disorder”, but this research has been stopped. Nothing on PubMed.
Bimekizumab (ucb4940) is a monoclonal antibody targeting IL-17A and IL-17F. S. Glatt and colleagues presented a study at the EULAR 2016 meeting in London. In this proof-of-concept-study bimekizumab demonstrated rapid onset and sustained efficacy on disease activity both in skin and joints. Adisinsight reports phase II studies in ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and rheumatoid arthritis as well as ulcerative colitis.
List will be completed over the next few months.
And don’t miss Wikipedia’s „List of therapeutic monoclonal antibodies”, which lists about a zillion MABs - https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies.